›› 2019, Vol. 39 ›› Issue (5): 510-.doi: 10.3969/j.issn.1674-8115.2019.05.012

• Original article (Clinical research) • Previous Articles     Next Articles

Clinical observation on prevention of pterygium recurrence with bleomycin in pterygium surgery

CHEN Jun-zhao, ZHAO Zhan-lin, YAO Qin-ke, SHAO Chun-yi, FU Yao   

  1. Department of Ophthalmology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine; Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai 200011, China
  • Online:2019-05-28 Published:2019-07-26
  • Supported by:
    National Natural Science Foundation of China, 81600774，81770888; Foundation of Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, 17DZ2260100; Shanghai Municipal Education Commission— GaoFeng Clinical Medicine Support, 20161421; Founda

PDF (PC)

385

Abstract: Objective · To observe the clinical effect of bleomycin for prevention of recurrence after pterygium treatment. Methods · Pterygium excision surgery combined with conjunctival autograft transplantation method on 59 patients (82 eyes) was performed, bleomycin (3 mg/mL) was used to prevent recurrence during the surgery. Corneal and conjunctival wound healing, recurrence rate and complications were observed in all the patients after surgery. Results · All the patients were followed-up for 6 months or more [(18.5±9.7) months]. After surgery, the corneas were transparent; the conjunctival flaps healed well and fused with surrounding tissues; no obvious scar hyperplasia and no recurrence of pterygium occured during the follow-up. None of the patients had sustained corneal epithelial defect, scleral ischemia, symblepharon, secondary glaucoma or cataract. Conclusion · The application of bleomycin may reduce the recurrence rate of pterygium effectively without serious complications.

Key words: pterygium, bleomycin, recurrence

CLC Number: